Cardiotoxicity in low-to-moderate cardiovascular risk patients undergoing anti-HER2 therapy: a prospective cardiac magnetic resonance study
It is common for patients with low-to-moderate cardiovascular risk to experience early cardiotoxicity during anti-HER2 therapy. T1 mapping was a valuable approach for quantifying the specific extent of subtle tissue damage.
Authors
- Linlin Qi (ORCID: https://orcid.org/0000-0001-5187-8401)
- Fan Yang (ORCID: https://orcid.org/0000-0002-1044-7821)
- Lizhi Xie (ORCID: https://orcid.org/0000-0002-4379-9348)
- Yawen Wang (ORCID: https://orcid.org/0000-0002-1306-8931)
- Jianwei Wang (ORCID: https://orcid.org/0000-0002-9511-0952)
- Jiaqi Chen (ORCID: https://orcid.org/0000-0002-0252-7987)
- Jianing Liu (ORCID: https://orcid.org/0000-0002-8394-2743)
- Sainan Cheng
- Shulei Cui
- Fenglan Li (ORCID: https://orcid.org/0000-0002-0090-4611)
- Mei Deng
Institutions
- General Electric (Spain) (ES)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
Publication Details
- Journal
- Radiology and Oncology
- Published
- 2025-10-27
- DOI
- https://doi.org/10.2478/raon-2025-0043
- Primary Topic
- Chemotherapy-induced cardiotoxicity and mitigation
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Chinese Academy of Medical Sciences
- Cancer Foundation of China